3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Pain
2
Neoplasms
2
Interventions
Radiotherapy
8
Zoledronic Acid
7
Fentanyl
7
nabiximols
6
Morphine
6
Ibandronic Acid
6
Ketamine
5
Hydromorphone
5
Analgesia
5
Acetaminophen
5
Tapentadol
4
Oxycodone
4
Acupuncture Therapy
4
alvimopan
3
Ropivacaine
3
Prednisone
3
Lidocaine
3
cabozantinib
2
Tetrodotoxin
2
Mitoxantrone
2
Gabapentin
2
Duloxetine Hydrochloride
2
Docetaxel
2
Calcium
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
strontium chloride
1
resiniferatoxin
1
oxycodone-acetaminophen
1
oxycodone naloxone combination
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Pain
×
Tetrodotoxin
×
Clear all
NCT00725114
2014-07-09
TEC-006
Wex Pharmaceuticals Inc.
Phase 3
Completed
165 enrolled
NCT00726011
2012-10-24
TEC-006OL
Wex Pharmaceuticals Inc.
Phase 3
Completed
113 enrolled